Your browser doesn't support javascript.
loading
Cerebrospinal fluid proteomic profiling of individuals with mild cognitive impairment and suspected non-Alzheimer's disease pathophysiology.
Delvenne, Aurore; Gobom, Johan; Tijms, Betty; Bos, Isabelle; Reus, Lianne M; Dobricic, Valerija; Kate, Mara Ten; Verhey, Frans; Ramakers, Inez; Scheltens, Philip; Teunissen, Charlotte E; Vandenberghe, Rik; Schaeverbeke, Jolien; Gabel, Silvy; Popp, Julius; Peyratout, Gwendoline; Martinez-Lage, Pablo; Tainta, Mikel; Tsolaki, Magda; Freund-Levi, Yvonne; Lovestone, Simon; Streffer, Johannes; Barkhof, Frederik; Bertram, Lars; Blennow, Kaj; Zetterberg, Henrik; Visser, Pieter Jelle; Vos, Stephanie J B.
  • Delvenne A; Department of Psychiatry and Neuropsychology, Alzheimer Centrum Limburg, School for Mental Health and Neuroscience, Maastricht University, Maastricht, the Netherlands.
  • Gobom J; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.
  • Tijms B; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
  • Bos I; Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, the Netherlands.
  • Reus LM; Department of Psychiatry and Neuropsychology, Alzheimer Centrum Limburg, School for Mental Health and Neuroscience, Maastricht University, Maastricht, the Netherlands.
  • Dobricic V; Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, the Netherlands.
  • Kate MT; Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, the Netherlands.
  • Verhey F; Lübeck Interdisciplinary Platform for Genome Analytics, University of Lübeck, Lübeck, Germany.
  • Ramakers I; Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, the Netherlands.
  • Scheltens P; Department of Radiology and Nuclear Medicine, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands.
  • Teunissen CE; Department of Psychiatry and Neuropsychology, Alzheimer Centrum Limburg, School for Mental Health and Neuroscience, Maastricht University, Maastricht, the Netherlands.
  • Vandenberghe R; Department of Psychiatry and Neuropsychology, Alzheimer Centrum Limburg, School for Mental Health and Neuroscience, Maastricht University, Maastricht, the Netherlands.
  • Schaeverbeke J; Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, the Netherlands.
  • Gabel S; Neurochemistry Laboratory, Department of Clinical Chemistry, Amsterdam University Medical Centers (AUMC), Amsterdam Neuroscience, the Netherlands.
  • Popp J; Neurology Service, University Hospitals Leuven, Leuven, Belgium.
  • Peyratout G; Laboratory for Cognitive Neurology, Department of Neurosciences, KU Leuven, Leuven, Belgium.
  • Martinez-Lage P; Neurology Service, University Hospitals Leuven, Leuven, Belgium.
  • Tainta M; Laboratory for Cognitive Neurology, Department of Neurosciences, KU Leuven, Leuven, Belgium.
  • Tsolaki M; Neurology Service, University Hospitals Leuven, Leuven, Belgium.
  • Freund-Levi Y; Laboratory for Cognitive Neurology, Department of Neurosciences, KU Leuven, Leuven, Belgium.
  • Lovestone S; Old Age Psychiatry, University Hospital Lausanne, Lausanne, Switzerland.
  • Streffer J; Department of Geriatric Psychiatry, Psychiatry University Hospital Zürich, Zürich, Switzerland.
  • Barkhof F; Old Age Psychiatry, University Hospital Lausanne, Lausanne, Switzerland.
  • Bertram L; Fundación CITA-Alzhéimer Fundazioa, San Sebastian, Spain.
  • Blennow K; Fundación CITA-Alzhéimer Fundazioa, San Sebastian, Spain.
  • Zetterberg H; 1st Department of Neurology, AHEPA University Hospital, Medical School, Faculty of Health Sciences, Aristotle University of Thessaloniki, Makedonia, Thessaloniki, Greece.
  • Visser PJ; Department of Neurobiology, Caring Sciences and Society (NVS), Division of Clinical Geriatrics, Karolinska Institutet, Stockholm, Sweden.
  • Vos SJB; Department of Psychiatry in Region Örebro County and School of Medical Sciences, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
Alzheimers Dement ; 2022 Jun 14.
Article en En | MEDLINE | ID: mdl-35698882
BACKGROUND: Suspected non-Alzheimer's disease pathophysiology (SNAP) is a biomarker concept that encompasses individuals with neuronal injury but without amyloidosis. We aim to investigate the pathophysiology of SNAP, defined as abnormal tau without amyloidosis, in individuals with mild cognitive impairment (MCI) by cerebrospinal fluid (CSF) proteomics. METHODS: Individuals were classified based on CSF amyloid beta (Aß)1-42 (A) and phosphorylated tau (T), as cognitively normal A-T- (CN), MCI A-T+ (MCI-SNAP), and MCI A+T+ (MCI-AD). Proteomics analyses, Gene Ontology (GO), brain cell expression, and gene expression analyses in brain regions of interest were performed. RESULTS: A total of 96 proteins were decreased in MCI-SNAP compared to CN and MCI-AD. These proteins were enriched for extracellular matrix (ECM), hemostasis, immune system, protein processing/degradation, lipids, and synapse. Fifty-one percent were enriched for expression in the choroid plexus. CONCLUSION: The pathophysiology of MCI-SNAP (A-T+) is distinct from that of MCI-AD. Our findings highlight the need for a different treatment in MCI-SNAP compared to MCI-AD.
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Idioma: En Año: 2022 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Idioma: En Año: 2022 Tipo del documento: Article